Traumatic injuries to the central nervous system can leave lasting neurological consequences because the brain and spinal cord have a limited capacity for regeneration. Following spinal cord injury (SCI) or traumatic brain injury (TBI), the initial mechanical damage is followed by a complex secondary cascade involving inflammation, excitotoxicity, mitochondrial dysfunction, oxidative stress and progressive cell death. Over time, these processes can create an environment that restricts axonal growth and limits the ability of neural circuits to reorganize. Markdown collé Markdown collé
This limited regenerative capacity has placed neuroplasticity at the center of research into neurological recovery. Cell-based therapies are emerging as particularly interesting approaches because their potential extends beyond replacing damaged cells. Different stem and progenitor cell populations may influence the injured microenvironment, modulate inflammation and provide biological signals that support neural repair. Markdown collé
Why Is Regeneration So Difficult After CNS Injury?
Recovery following CNS trauma is constrained by both intrinsic neuronal mechanisms and an inhibitory extracellular environment.
Mature neurons have limited ability to reactivate the molecular programs required for axonal regeneration. Changes involving pathways such as PTEN, PI3K/Akt and mTOR can restrict neuronal survival and neurite extension. At the same time, extracellular signals associated with damaged myelin can trigger cytoskeletal changes that cause growth cone retraction and inhibit neurite growth. Markdown collé
The formation of a glial scar adds another layer of complexity. Reactive astrocytes and extracellular components, including chondroitin sulfate proteoglycans, can create a physical and molecular barrier to axonal regrowth. However, this response is not exclusively detrimental: reactive astrocytes can also help contain tissue damage, restrict inflammation and preserve tissue integrity. Markdown collé
Restoring function therefore requires more than generating new cells. The surrounding biological environment must also become sufficiently permissive for survival, axonal growth, remyelination and neural circuit reorganization.
Cell Therapies Can Act on Multiple Repair Mechanisms
Several cell populations are being investigated for their capacity to influence this complex environment.
Mesenchymal stem cells (MSCs) are among the most extensively explored. Cells derived from bone marrow, umbilical cord and adipose tissue have demonstrated multiple effects in preclinical SCI models, including modulation of inflammatory signaling, reduction of neuronal death, support of angiogenesis and secretion of neurotrophic factors. Markdown collé
Rather than acting through a single pathway, these cells can simultaneously influence several components of the secondary injury response. This is particularly relevant because CNS trauma involves interconnected inflammatory, vascular, metabolic and degenerative processes.
In TBI models, MSC-based approaches have similarly been associated with improvements in sensorimotor and cognitive outcomes, together with reductions in anatomical damage. Their effects are largely linked to paracrine activity, including the secretion of immunomodulatory cytokines and neurotrophic and angiogenic factors that support cell survival, neurogenesis and a more regenerative tissue environment. Markdown collé
Neural Stem and Progenitor Cells Offer a Different Route to Repair
While MSCs are strongly associated with modulation of the injury environment, neural stem cells (NSCs) and neural progenitor cells (NPCs) introduce the possibility of directly supporting neural reconstruction.
In preclinical SCI models, NSCs have been reported to differentiate into neurons capable of extending long-distance axons and forming synaptic connections. They can also secrete trophic factors such as NGF, BDNF and GDNF, providing additional support for host axon survival and growth. Markdown collé
NPCs may contribute to corticospinal tract regeneration by bridging lesions and attenuating glial scarring. These characteristics make neural stem and progenitor cells particularly interesting for strategies that aim not only to protect remaining tissue but also to rebuild elements of damaged neural networks. Markdown collé
Another population, olfactory ensheathing cells, has demonstrated neurotrophic and regenerative properties associated with axonal guidance, modulation of early immune responses and remyelination of spared axons. Markdown collé
Despite their biological differences, these approaches converge toward several common objectives: neuroprotection, modulation of inflammation and functional tissue repair. Markdown collé
From Living Cells to Their Secreted Signals
An important evolution in this field is the growing interest in the biological products released by therapeutic cells.
The secretome encompasses soluble and vesicular components produced through paracrine signaling, including growth factors, cytokines, enzymes, bioactive lipids, metabolites and regulatory microRNAs. These components can participate in angiogenesis, anti-inflammatory signaling, neuroprotection and anti-apoptotic mechanisms. Markdown collé
Extracellular vesicles (EVs) represent an important component of these cell-derived strategies. In preclinical SCI models, MSC-derived EVs have been associated with reduced inflammatory signaling, preservation of tissue barriers, decreased neuronal apoptosis and improved functional outcomes. Different MSC-derived secretomes and EV populations have also demonstrated effects on axonal regeneration, vascular support and immune modulation. Markdown collé
Similar observations have been reported in preclinical TBI models, where MSC secretome-based approaches have been associated with reduced neuroinflammation, smaller contusion volumes, increased neurogenesis and improvements in motor and cognitive outcomes. Markdown collé
These findings broaden the concept of cell therapy: the therapeutic value of a cell may reside not only in its capacity to engraft or differentiate, but also in the complex biological signals it produces.
Translation to the Clinic Remains Challenging
Despite encouraging preclinical findings, translating these approaches into standardized therapies remains complex.
Clinical studies in SCI have investigated a broad range of cell populations, including BMSCs, HSCs, UCMSCs, adipose-derived stem cells, NSCs, NPCs and olfactory ensheathing cells. Among these approaches, bone marrow-derived MSCs currently have one of the largest clinical evidence bases, although differences between trials make definitive comparisons difficult. Markdown collé
For TBI, the clinical evidence remains more limited. Studies differ considerably in cell source, dose, administration route, timing and follow-up, while many involve small cohorts, non-randomized designs or insufficient control groups. These limitations prevent firm conclusions regarding efficacy. Markdown collé
Timing represents another major challenge. Preclinical interventions frequently target acute secondary injury processes, whereas clinical administration may occur considerably later because of medical and logistical constraints. This difference can substantially influence therapeutic outcomes. Markdown collé
Standardization Is Essential for the Future of CNS Cell Therapy
The cellular product itself introduces additional variability.
Differences in donor characteristics, harvesting procedures and culture conditions can affect cell populations and make therapeutic outcomes more difficult to standardize. Limited graft survival and persistence, immune-related risks and variability in preparation and delivery remain important considerations. Markdown collé
At the manufacturing level, both cell-based and secretome-based strategies must ultimately transition toward scalable production under Good Manufacturing Practice conditions, supported by rigorous quality control. Markdown collé
This makes reproducible cell production an important part of the translational pathway. As these therapies progress, greater standardization of cell preparation, dose, administration route and therapeutic timing will be necessary alongside larger and better-controlled clinical trials. Markdown collé
Toward Restoring the Regenerative Potential of the CNS
Cell therapy is opening new possibilities for addressing one of the fundamental challenges of CNS trauma: creating conditions in which neural repair and plasticity can occur despite an intrinsically restrictive environment.
Across different cellular strategies, therapeutic mechanisms converge around several interconnected objectives: limiting secondary damage, modulating inflammation, supporting neuronal survival, promoting axonal growth, encouraging neurogenesis and remyelination, and ultimately facilitating the reorganization of neural circuits. Markdown collé
The field remains at different stages of maturity for SCI and TBI, and clinical translation is not yet complete. Nevertheless, the growing diversity of stem cell, progenitor cell and cell-derived strategies illustrates a broader shift in regenerative neuroscience: from attempting to replace damaged tissue alone toward actively reshaping the post-injury environment to support the CNS’s own capacity for plasticity and repair.
Scientific background: Restoring neuroplasticity after CNS trauma: cell therapy approaches in spinal cord and traumatic brain injury, 2026.
, 2020.
